fighting-tigers
30 April 2014AsiaArchana Shanker

The Copaxone battle: an update

Copaxone (glatiramer acetate) is a blockbuster drug for the treatment of multiple sclerosis, created by Yeda Research and Development Co Ltd. The patents that cover Copaxone, including the process for its preparation, have been extensively litigated around the globe, and in India the patent for the preparation of Copaxone expires on May 23, 2015. For this process patent, several proceedings are currently pending before various bodies in India, including the Delhi High Court, the Intellectual Property Appellate Board and the Indian Patent Office (IPO).

Already registered?

Login to your account

To request a FREE 2-week trial subscription, please signup.
NOTE - this can take up to 48hrs to be approved.

Two Weeks Free Trial

For multi-user price options, or to check if your company has an existing subscription that we can add you to for FREE, please email Adrian Tapping at atapping@newtonmedia.co.uk


More on this story

Asia
3 July 2026   A report warns that procurement reforms in Mainland China, alongside the rise of open robotics platforms, supply chain disruption and GLP-1 drugs, are challenging existing medtech business models.
Asia
22 June 2026   The court granted Blue Cross Laboratories a permanent injunction after finding that a rival product’s mark and packaging closely mirrored its own.
Asia
27 May 2026   China’s IP system is undergoing real change. Takeda’s IP head for the region explains what that looks like on the ground and why the old playbook no longer cuts it.